Brief: Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation For The Treatment Of Mild Alzheimer’S Disease
10/07/2024 12:53
July 10 (Reuters) - Longeveron Inc LGVN.O :
* LONGEVERON® ANNOUNCES U.S. FDA GRANTS
LOMECEL-B™ REGENERATIVE
MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR THE TREATMENT
OF MILD ALZHEIMER’S DISEASE
Source text for Eikon: ID:nGNX64RqRK
Further company coverage: LGVN.O
((Reuters.Briefs@thomsonreuters.com;))